OCGN [NASD]
Ocugen, Inc.
Index- P/E- EPS (ttm)-0.35 Insider Own0.40% Shs Outstand216.59M Perf Week4.96%
Market Cap262.70M Forward P/E- EPS next Y-0.39 Insider Trans-29.26% Shs Float215.47M Perf Month14.41%
Income-74.00M PEG- EPS next Q-0.10 Inst Own37.90% Short Float / Ratio20.70% / 8.72 Perf Quarter-27.84%
Sales- P/S- EPS this Y2.30% Inst Trans-3.59% Short Interest44.59M Perf Half Y-51.53%
Book/sh0.44 P/B2.89 EPS next Y5.40% ROA-59.90% Target Price5.33 Perf Year-59.68%
Cash/sh0.49 P/C2.59 EPS next 5Y- ROE-67.80% 52W Range1.09 - 4.53 Perf YTD-2.31%
Dividend- P/FCF- EPS past 5Y65.20% ROI- 52W High-71.96% Beta3.90
Dividend %- Quick Ratio7.20 Sales past 5Y- Gross Margin- 52W Low16.51% ATR0.09
Employees56 Current Ratio7.20 Sales Q/Q- Oper. Margin- RSI (14)48.47 Volatility5.95% 7.68%
OptionableYes Debt/Eq0.00 EPS Q/Q-87.10% Profit Margin- Rel Volume0.91 Prev Close1.20
ShortableYes LT Debt/Eq0.02 EarningsNov 08 BMO Payout- Avg Volume5.11M Price1.27
Recom2.20 SMA201.24% SMA50-8.42% SMA200-37.75% Volume4,664,988 Change5.83%
Aug-23-22Initiated Mizuho Buy $5
Jun-15-22Resumed ROTH Capital Buy $8
Jun-02-22Initiated Cantor Fitzgerald Overweight $4.50
Jul-26-21Initiated Noble Capital Markets Outperform
Jun-11-21Downgrade ROTH Capital Buy → Neutral $10 → $6
May-07-21Downgrade Cantor Fitzgerald Overweight → Neutral
Feb-09-21Downgrade Chardan Capital Markets Buy → Neutral $0.70 → $13
Feb-04-21Upgrade H.C. Wainwright Neutral → Buy $4.50
Jan-26-23 05:21AM
Jan-23-23 05:21AM
Jan-11-23 07:03AM
Jan-09-23 08:33AM
06:22AM
06:16AM Loading…
06:16AM
06:00AM
Dec-29-22 03:39PM
Dec-25-22 03:58PM
Dec-16-22 06:30AM
Dec-15-22 05:15PM
Dec-13-22 08:00AM
Dec-07-22 08:00AM
Nov-28-22 07:30AM
Nov-17-22 09:23AM
06:16PM Loading…
Nov-09-22 06:16PM
Nov-08-22 06:30PM
01:00PM
07:30AM
Nov-07-22 08:17AM
Nov-02-22 05:21AM
Nov-01-22 07:42PM
Oct-27-22 07:30AM
Oct-19-22 07:30AM
Oct-12-22 05:37PM
Oct-06-22 09:25AM
08:00AM
Sep-29-22 07:30AM
Sep-28-22 12:28PM
09:44AM
06:30AM Loading…
06:30AM
Sep-16-22 05:07PM
Sep-14-22 06:30AM
Sep-08-22 07:30AM
Sep-06-22 07:30AM
Sep-01-22 06:28PM
07:30AM
Aug-24-22 03:36PM
Aug-23-22 09:08AM
Aug-13-22 09:45AM
Aug-12-22 10:30AM
07:30AM
Aug-06-22 05:31AM
Aug-05-22 07:30AM
Aug-03-22 05:06PM
Jul-29-22 03:27PM
07:30AM
Jul-14-22 12:30PM
Jul-13-22 12:25PM
Jul-12-22 11:20AM
Jul-08-22 04:48PM
Jun-21-22 12:47PM
10:22AM
09:31AM
07:00AM
Jun-15-22 05:56AM
Jun-14-22 07:00AM
Jun-13-22 07:00AM
Jun-10-22 06:39PM
Jun-09-22 06:17PM
Jun-07-22 07:29AM
May-31-22 01:56PM
May-30-22 12:53PM
May-28-22 06:30AM
May-26-22 11:07AM
May-24-22 11:30AM
09:30AM
07:11AM
May-23-22 10:11AM
08:53AM
07:34AM
07:28AM
06:50AM
06:36AM
May-18-22 06:30AM
May-13-22 07:10AM
May-06-22 12:30PM
07:45AM
06:33AM
May-02-22 07:37AM
Apr-30-22 11:15AM
Apr-29-22 11:36AM
Apr-28-22 11:00AM
09:45AM
09:05AM
Apr-27-22 05:06AM
Apr-25-22 07:33AM
Apr-19-22 05:32PM
05:21AM
Apr-18-22 07:25PM
09:30AM
07:11AM
Apr-17-22 11:30AM
Apr-14-22 01:34PM
Apr-13-22 09:55AM
Apr-12-22 10:00AM
09:28AM
09:11AM
08:31AM
Apr-08-22 12:15PM
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Musunuri ShankarChief Executive OfficerJan 17Option Exercise0.51100,00051,0002,327,950Jan 19 04:12 PM
Musunuri ShankarChief Executive OfficerJan 17Sale1.28100,000128,0002,227,950Jan 19 04:12 PM
Musunuri ShankarChief Executive OfficerDec 16Option Exercise0.5195,80948,863848,349Dec 20 04:07 PM
Musunuri ShankarChief Executive OfficerDec 16Sale1.4395,809137,007752,540Dec 20 04:07 PM
Musunuri ShankarChief Executive OfficerOct 14Option Exercise0.51100,00051,000852,540Oct 14 04:15 PM
Musunuri ShankarChief Executive OfficerOct 14Sale1.66100,000166,000752,540Oct 14 04:15 PM
Kumar RameshDirectorOct 06Option Exercise0.514,5002,2954,500Oct 07 04:06 PM
Kumar RameshDirectorOct 06Sale1.834,5008,2350Oct 07 04:06 PM
Castillo KirstenDirectorAug 11Option Exercise0.2842,00011,76092,000Aug 12 04:49 PM
Castillo KirstenDirectorAug 11Sale2.9142,000122,22050,000Aug 12 04:49 PM
Kumar RameshDirectorJul 18Option Exercise0.517,5003,8257,500Jul 20 04:19 PM
Kumar RameshDirectorJul 18Sale2.577,50019,2750Jul 20 04:19 PM
Musunuri ShankarChief Executive OfficerJul 14Option Exercise0.33150,00049,500902,540Jul 15 04:03 PM
Musunuri ShankarChief Executive OfficerJul 14Sale2.72150,000408,000752,540Jul 15 04:03 PM
Musunuri ShankarChief Executive OfficerMay 13Option Exercise0.33125,00041,250877,540May 13 04:02 PM
Musunuri ShankarChief Executive OfficerMay 13Sale1.92125,000240,000752,540May 13 04:02 PM
Kumar RameshDirectorApr 18Option Exercise0.517,5003,8257,500Apr 20 04:03 PM
Kumar RameshDirectorApr 18Sale2.837,50021,2250Apr 20 04:03 PM
Musunuri ShankarChief Executive OfficerMar 16Option Exercise0.3381,82327,002834,363Mar 18 04:03 PM
Musunuri ShankarChief Executive OfficerMar 16Sale2.6581,823216,831752,540Mar 18 04:03 PM
Zhang JungeDirectorMar 03Option Exercise1.2588,000109,56088,000Mar 04 04:03 PM
Musunuri ShankarChief Executive OfficerFeb 14Option Exercise0.3390,00029,700842,540Feb 16 04:03 PM
Musunuri ShankarChief Executive OfficerFeb 14Sale3.7490,000336,600752,540Feb 16 04:03 PM